Add-on Therapy With HMG-Coa-Reductase Inhibitors May Lower the Risk for Incident Left Ventricular Dysfunction +/− Heart Failure in Epirubicin Recipients With Gastric Cancer

Tase, Adrian; Titus, Ovidiu T.; Săvoiu, Gheorghe; Iorga-Siman, Ion; Mihaila, Marius

doi:10.1016/s0735-1097(14)60932-3

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of seven studies with 3042 subjects (1382 subjects received the concurrent statin) were included in our meta-analysis [17][18][19][20][21][22][23]. The main characteristics of the included studies are described in Table 1.…”

Section: Description Of the Included Studies And Quality Assessmentmentioning

confidence: 99%

“…In regards to the incidence of cardiomyopathy, the study by Calvillo-Argüelles et al [19] and Abdel-Qadir et al [17] provided the value of OR and its corresponding 95% CI. In the studies by Acar et al [18], Seicean et al [22], and Tase et al [23], the raw data for the number of subjects with CIC in the control and the statin groups are provided, and calculations were manually performed to obtain the OR and its corresponding 95% CI. NOS of the five selected studies ranged from 6 to 9 with a mean score of 8, reflecting a high quality of these studies.…”

Section: Description Of the Included Studies And Quality Assessmentmentioning

confidence: 99%

“…Some individual studies have suggested that statins may also play an important role in decreasing the risk of CIC [17][18][19][20][21][22][23]. To the best of our knowledge, there is no meta-analysis that studied the overall pooled cardioprotective effect of statins against CIC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis

Kim

Nishimura

Kewcharoen

et al. 2021

JCM

View full text Add to dashboard Cite

There is insufficient evidence about the cardioprotective effects of statins against chemotherapy-induced cardiomyopathy. The MEDLINE and EMBASE databases were searched from inception to March 2021 for studies that reported the mean left ventricular ejection fraction (LVEF) before and after chemotherapy and the incidence of chemotherapy-induced cardiotoxicity in patients who received concurrent statin therapy and those who received chemotherapy alone. A random effects meta-analysis was performed to obtain the pooled weighted mean difference (WMD) and the 95% confidence interval (CI) for the mean final LVEF and the mean LVEF change, and the pooled odds ratio (OR) and the 95% CI of the incidence of chemotherapy-induced cardiomyopathy. Seven studies with 3042 patients were included in this meta-analysis (statin group: 1382 patients received concurrent statin with chemotherapy; control group: 1660 patients received chemotherapy alone). Patients in the control group had a more significant decline in LVEF (WMD = −6.08%, 95% CI: −8.55 to −3.61, p < 0.001) compared to those in the statin group. Additionally, the statin group had a significantly lower incidence of chemotherapy-induced cardiomyopathy compared to the control group (OR = 0.41, 95% CI = 0.28–0.60, p < 0.001). Consequently, our study showed a significant reduction in the incidence of chemotherapy-induced cardiomyopathy and the degree of LVEF decline in patients in the statin group compared to those in the control group.

show abstract

Section: Description Of the Included Studies And Quality Assessmentmentioning

confidence: 99%

Section: Description Of the Included Studies And Quality Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis

Kim

Nishimura

Kewcharoen

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

Add-on Therapy With HMG-Coa-Reductase Inhibitors May Lower the Risk for Incident Left Ventricular Dysfunction +/− Heart Failure in Epirubicin Recipients With Gastric Cancer

Cited by 1 publication

References 0 publications

Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis

Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About